pre-IPO PHARMA

COMPANY OVERVIEW

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Founded by world-leading experts in cardiovascular medicine and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, and Biomatics Capital. Verve is headquartered in Cambridge, Massachusetts, and has a research lab located at Pennovation Works, the University of Pennsylvania incubator space in Philadelphia.


LOCATION

  • Cambridge, MA, USA
  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Caridovascular Disease

  • WEBSITE

    https://www.vervetx.com


    CAREER WEBSITE

    https://www.vervetx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    arch-venture-partners biomatics-capital f-prime-capital-partners gv


    PRESS RELEASES


    Jun 16, 2021

    Verve Therapeutics Announces Pricing of Initial Public Offering


    Jun 1, 2021

    Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors


    Jun 1, 2021

    Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease


    May 19, 2021

    Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates


    May 11, 2021

    Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT


    For More Press Releases


    Google Analytics Alternative